The prognosis of locally advanced or metastatic colorectal cancer (mCRC) with wild-type (WT) RAS has improved due to the introduction of new targeted therapies such as epidermal growth factor receptor (EGFR) inhibitors. The gene discussed is EGFR; the disease is metastatic colorectal cancer.